Several studies have linked elevated levels of serum C-peptide (a stable marker of insulin secretion that is co-secreted with insulin) with enhanced risk of post-menopausal endometrial cancer, colorectal cancer and breast cancer, but not pre-menopausal, ovarian, breast and prostate cancers. This evidence concerns the gene INS and breast carcinoma.